The calculation of a confidence interval on the absolute estimated benefit for an individual patient

Computers and Biomedical Research

Volumn 31, Issue 4, 1998, Pages 244-256

  Li, Wei ^a   Girard, Pascal ^a   Boissel, Jean Pierre ^a   Gueyffier, François ^a  

^a Service de Pharmacologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; HUMAN; MATHEMATICAL COMPUTING; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEM ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031714492     PISSN: 00104809     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbmr.1998.1477     Document Type: Article

References (42)

1. Christensen, E., Neuberger, J., Growe, J., Altman, D. G., Popper, H., Portmann, B., Doniach, D., Ranek, L., Tygstrup, N., and Williams, R. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Gastroenterol. 89, 1084 (1985).
2. Vonesh, E. F. Modelling peritonitis rates and associated risk factors for individuals on continuous ambulatory peritoneal dialysis. Stat. Med. 9, 263 (1990).
3. Lee, Y. J., Ellenberg, J. H., Hirtz, D. G., and Nelson, K. B. Analysis of clinical trials by treatment actually received: Is it really an option? Stat. Med. 10, 1595 (1991).
4. Mirabel-Sarron, C., Brun-Eberentz, A., and Samuel-Lajeunesse, B. Recherches d'indices psychologiques prédictifs de la réponse à la thérapie cognitive. Ann. Méd. Psychol. 1, 153 (1995).
5. Byar, D. P., and Corle, D. K. Selecting optimal treatment in clinical trials using covariate information. J. Chron. Dis. 30, 445 (1977).
6. Barbosa, M. D. M. A methodology for finding optimal dosage levels in multi-drug treatment interactions. Comput. Methods Programs Biomed. 43, 239 (1994).
7. Spiegelhalter, D. J. Probabilistic prediction in patient management and clinical trials. Stat. Med. 5, 421 (1986).
8. Young, M. A., and Fogg, L. F. Predicting response to treatment: Differentiating active-factor and non-specific effects. Stat. Med. 9, 253 (1990).
9. Byar, D. P., and Green, S. B. The choice of treatment for cancer patients based on covariate information: Application to prostate cancer. Bull. Cancer (Paris) 4, 477 (1980).
10. Christensen, E., Schlichting, P., Andersen, P. K., Fauerholdt, L., Juhl, E., Poulsen, H., Tygstrup, N., and the Copenhagen Study Group for Liver Diseases. A therapeutic index that predicts the individual effects of prednisone in patients with cirrhosis. Gastroenterol. 88, 156-165 (1985).
11. Schlichting, P., Christensen, E., Andersen, P. K., Fauerholdt, L., Juhl, E., Poulsen, H., Tygstrup, N., and the Copenhagen Study Group for Liver Diseases. Prognostic factors in Cirrhosis identified by Cox's regression model. Hepatology 3, 889 (1983).
12. Christensen, E., Schlichting, P., Andersen, P. K., Fauerholdt, L., Schou, G., Pedersen, B. V., Juhl, E., Poulsen, H., Tygstrup, N., and the Copenhagen Study Group for Liver Diseases. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox's multiple regression model for time-dependent variables. Scand. J. Gastroenterol. 21, 163 (1986).
13. Sharp, S. J., Thompson, S. G., and Altman, D. G. The relation between treatment benefit and underlying risk in meta-analysis. Br. Med. J. 313, 735 (1996).
14. Antiplatelet Trialist's Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308, 81 (1994).
15. Antman, E. M., Lau, J., Kupelnick, B., Mosteller, F., and Chalmers T. C. A comparison of results of meta analysis of randomized control trial and recommendations of clinical experts. Treatments for myocardial infarction. J. Am. Med. Assoc. 268, 240 (1992).
16. Smith, P., Arnessen, H., and Holme, I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New England J. Med. 323, 147-152 (1990). Anticoagulant in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long- term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343, 499 (1994).
17. Smith, P., Arnessen, H., and Holme, I. The effect of warfarin on mortality and reinfarction after myocardial infarction. New England J. Med. 323, 147-152 (1990). Anticoagulant in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343, 499 (1994).
18. Glasziou, P. P., and Irwig, L. M. An evidence based approach to individualizing treatment. Br. Med. J. 311, 1356 (1995).
19. Boissel, J. P., Collet, J. P., Lievre, M., and Girard, P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J. Cardio. Pharmacol. 22, 356 (1993).
20. Hoes, A. W., Grobbee, D. E., and Lubsen, J. Does drug treatment improve survival? Reconciling the trials in mild to moderate hypertension. J. Hypertension 13, 805 (1995).
21. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group - ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345, 669 (1995).
22. Naylor, C. D., Chen, E., and Strauss, B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann. Int. Med. 117, 916 (1992).
23. Jackson, R., Barham, P., Maling, T., Bills, J., Birch, T., Mclennan, L., Macmahon, S., and Maling, T. Management of raised blood pressure in New Zealand. Br. Med. J. 307, 107 (1993).
24. Anderson, K. M., Wilson, P. W. F., Odell, P. W., and Kannel, W. B. An updated coronary risk profile: a statement for health professionals. Circulation 83, 356 (1991).
25. Li, W., Boissel, J. P., Girard, P., Boutitie, F., Cucherat, M., and Gueyffier, F. Identification and prediction of responders to a therapy: a model and its preliminary application to actual data. Revision in J. Epidemiol. Stat. in press.
26. Peter, F. T., and John, M. L. Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat. Med. 5, 73 (1986).
27. Collett, D. "Modeling Survival Data in Medical Research." Chapman & Hall, London, 1995.
28. Efron, B., and Tibshirani, R. J. "An Introduction to the Bootstrap." Chapman & Hall, New York, 1993.
29. Laurence, T. M. Confidence intervals for the parameters of psychometric functions. Percept. Psychophys. 47, 127 (1990).
30. SAS Institute, Inc. "SAS® SAS/STAT Software: Changes and Enhancements." Through Release 6.11. SAS Institute Inc., Cary, NC, 1996.
31. Mathsoft, Inc. "S-PLUS Version 3.3 for Windows," Seattle, Washington, StatSci Division, Math-Soft, Inc., 1995.
32. Gueyffier, F., Boutitie, F., Boissel, J. P., Coope, J., Cutler, J., Ekbom, T., Fagard, R., Friedman, L., Perry, H. M., Pocock, S., Prineas, R., and Schron, E. INDANA: a meta-analysis on individual patients data in hypertension. Protocol and preliminary results. Thérapie (Paris) 50, 353 (1995).
33. Altman, D. G. Bootstrap investigation of the stability of a Cox regression model. Stat. Med. 8, 771 (1989).
34. Chen, C. H., and George, S. L. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat. Med. 4, 39 (1985).
35. Efron, B. Nonparametric standard errors and confidence intervals. Can. J. Stat. 2, 139 (1981).
36. Gelber, R. D., Goldhirsch, A., and Cole, B. F. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatment. Control. Clin. Trials 14, 485 (1993).
37. Forrow, L., Taylor, W. C., and Arnold, R. M. Absolute relative: how research results are summarized can affect treatment decisions. Am. J. Med. 92, 121 (1992).
38. Bobbio, M., Demichelis, B., and Giusetto, G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 343, 1209 (1994).
39. Schulzer, M., and Mancini, G. B. 'Unqualified success' and 'unmitigated failure': number- needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int. J. Epidemiol. 25(4), 704 (1996).
40. Buyse, M., Boissel, J. P., and Cucherat, M. How should treatment efficacy be reported? A comparison of indices. Submitted.
41. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339, 1 and 72 (1992).
42. Tsiatis, A. A. A large sample study of Cox's regression model. Ann. Statist. 9, 93 (1981).